Scrip
21 May 2009
Sue Sutter
A webcast video for Johnson & Johnson's opioid analgesic Ultram ER (tramadol extended release) minimises the drug's serious risks and overstates its efficacy, the US FDA said in a recent warning letter.
The letter criticises the video for presenting a lack of balanced information...
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA panels vote against Jazz bid to sell sodium oxybate for fibromyalgia
- FDA seeks balance between flexibility and adequacy in proposed drug risk standards for broadcast DTC ads
- US FDA warns Eisai for overstating efficacy of Dacogen in promotion
- US FDA warns Sanofi-Aventis over misleading Uroxatral promotion
COMMENT
Other Informa Comment
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
